In 1991, CB Research and Development was founded in a 2,000-square-foot facility to synthesize specialized chemical compounds for drug-makers. There were three employees. That…
Incyte Corporation has announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi® (ruxolitinib) for the treatment of steroid-refractory acute GVHD in…
Incyte Corporation, one of the region’s largest pharmaceutical companies, today reported fourth-quarter and year-end financial gains for 2016. The company attributes the success, in…
WILMINGTON — Incyte Corporation, based in Wilmington, has announced the first patient has been treated in the REACH-1 pivotal Phase 2 trial evaluating its…